Achieve Life Sciences Announces Participation in February Investor Conferences

Rhea-AI Summary

Achieve Life Sciences (NASDAQ: ACHV) is participating in the Winter Wonderland Best Ideas Virtual Investor Conference on February 8, 2022, at 2:00 PM EST and the Aegis Virtual Conference on February 25, 2022, also at 2:00 PM EST. The company focuses on developing cytisinicline, a plant-based treatment aimed at smoking cessation and nicotine addiction. Tobacco use is a leading cause of preventable deaths worldwide. Cytisinicline is an investigational product candidate and has yet to receive FDA approval for any use in the U.S. For more details, visit Achieve's website.

Positive

• Participation in two significant virtual investor conferences may enhance visibility and investor relations.
• Focus on developing cytisinicline addresses a major global health issue, presenting potential market opportunities.

Negative

• Cytisinicline has not yet received FDA approval, which poses a risk to commercialization efforts.
• Forward-looking statements indicate several risks including potential inability to secure financing and the need for strategic adjustments.

SEATTLE and VANCOUVER, British Columbia, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will be participating in the Winter Wonderland Best Ideas Virtual Investor Conference and Aegis Virtual Conference during February 2022. 

Winter Wonderland Best Ideas Virtual Investor Conference 
Date: Tuesday, February 8, 2022
Time: 2:00 PM EST
Event: Presentation

For more information and to arrange one-on-one meetings, please visit https://microcaprodeo.com/

Aegis Virtual Conference 
Date: Friday, February 25, 2022
Time: 2:00 PM EST
Event: Presentation 

To access the event, please download and import the following iCalendar (.ics) files to your calendar system: Aegis Virtual Conference Calendar

About Achieve and Cytisinicline  
Tobacco use is currently the leading cause of preventable death that is responsible for more than eight million deaths worldwide and nearly half a million deaths in the United States annually.^1,2 More than 87% of lung cancer deaths, 61% of all pulmonary disease deaths, and 32% of all deaths from coronary heart disease are attributable to smoking and exposure to secondhand smoke.² Achieve’s focus is to address the global smoking health and nicotine addiction epidemic through the development and commercialization of cytisinicline. 
  
Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in smoking cessation by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms and by reducing the reward and satisfaction associated with smoking. 
  
Cytisinicline is an investigational product candidate being developed for treatment of nicotine addiction and has not been approved by the Food and Drug Administration for any indication in the United States. For more information on cytisinicline and Achieve, visit www.achievelifesciences.com. 

Forward Looking Statements 
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the timing and nature of cytisinicline clinical development, data results and commercialization activities, the potential market size for cytisinicline, the potential benefits, safety and tolerability of cytisinicline, the ability to discover and develop new uses for cytisinicline, including but not limited to as an e-cigarette cessation product, and the development and effectiveness of new treatments. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Achieve may not actually achieve its plans or product development goals in a timely manner, if at all, or otherwise carry out its intentions or meet its expectations or projections disclosed in these forward-looking statements. These statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including, among others, the risk that cytisinicline may not demonstrate the hypothesized or expected benefits; the risk that Achieve may not be able to obtain additional financing to fund the development of cytisinicline; the risk that cytisinicline will not receive regulatory approval or be successfully commercialized; the risk that new developments in the smoking cessation landscape require changes in business strategy or clinical development plans; the risk that Achieve’s intellectual property may not be adequately protected; general business and economic conditions; risks related to the impact on our business of the COVID-19 pandemic or similar public health crises and the other factors described in the risk factors set forth in Achieve’s filings with the Securities and Exchange Commission from time to time, including Achieve’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. Achieve undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable. 
  
Investor Relations Contact 
Rich Cockrell 
achv@cg.capital 
(404) 736-3838 
  
Media Contact 
Glenn Silver 
Glenn.Silver@Finnpartners.com 
(646) 871-8485 

References  
¹ World Health Organization. WHO Report on the Global Tobacco Epidemic, 2019. Geneva: World Health Organization, 2017.  
² U.S. Department of Health and Human Services. The Health Consequences of Smoking – 50 Years of Progress. A Report of the Surgeon General, 2014.   

FAQ

What are the dates for the Winter Wonderland Best Ideas Virtual Investor Conference and Aegis Virtual Conference for ACHV?

The Winter Wonderland Best Ideas Virtual Investor Conference is on February 8, 2022, and the Aegis Virtual Conference is on February 25, 2022.

What is ACHV's focus in developing cytisinicline?

ACHV focuses on developing cytisinicline for smoking cessation and nicotine addiction.

Is cytisinicline approved by the FDA?

No, cytisinicline is an investigational product candidate and has not received FDA approval in the United States.

What potential risks are associated with ACHV's forward-looking statements?

Risks include potential failure to secure financing, inability to obtain regulatory approval for cytisinicline, and the need for strategic changes.